NEW TRIAL RECRUITING PRIMARY, POST-PV, AND POST-ET MYELOFIBROSIS PATIENTS

  • MPNRF | April 6, 2021

    Official Title: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib 

    CTI Biopharma is recruiting patients for the PACIFCA trial, a randomized phase 3 study evaluating Pacritinib in patients with myelofibrosis and less than 50,0000 platelet count who have never received a JAK2 inhibitor or who have had no more than 90 days of prior JAK2 inhibitor exposure.

    CLICK HERE FOR MORE INFORMATION.